| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -34.4 | -56.8 |
| Net income | -34.4 | -56.8 |
| EPS (diluted, $ a share) | $-0.18 | $-0.35 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: NMRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Neumora Therapeutics, Inc.: key numbers
- Share price
- $0.3345Close, Nov 17
- Market cap
- $63.1M
- Shares outstanding
- 188.69MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Neumora Therapeutics, Inc.
All →Neumora Therapeutics Business Update
Neumora Therapeutics reported third quarter 2026 financial results and provided a pipeline update, including the submission of an IND application for NMRA-215 in obesity. The company reported a cash position of $85.7 million and noted that it will require substantial additional funding to continue operations and complete product development.
Neumora Therapeutics Nasdaq/NYSE Compliance Notice
Neumora Therapeutics received a deficiency notice from Nasdaq for failing to maintain the $1.00 minimum bid price requirement for its common stock. The company has 180 calendar days, until April 26, 2027, to regain compliance by having its stock close at $1.00 or higher for at least ten consecutive business days.
- Counterparty
- The Nasdaq Stock Market LLC
- Term
- 180 days